Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.

Guardado en:

Detalles Bibliográficos
Autores principales:	Mencinger Marina, Mangaroski Dusan, Bokal Urska
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2021
Materias:	pd-l1 inhibitor urothelial cancer bladder atezolizumab overall survival immune checkpoint inhibitor prognostic factors Medical physics. Medical radiology. Nuclear medicine R895-920
Acceso en línea:	https://doaj.org/article/e129ffa1f0f8468498cf304d0108d71e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e129ffa1f0f8468498cf304d0108d71e
record_format	dspace
spelling	oai:doaj.org-article:e129ffa1f0f8468498cf304d0108d71e2021-12-05T14:11:10ZDisease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice1581-320710.2478/raon-2021-0021https://doaj.org/article/e129ffa1f0f8468498cf304d0108d71e2021-05-01T00:00:00Zhttps://doi.org/10.2478/raon-2021-0021https://doaj.org/toc/1581-3207Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.Mencinger MarinaMangaroski DusanBokal UrskaSciendoarticlepd-l1 inhibitorurothelial cancerbladderatezolizumaboverall survivalimmune checkpoint inhibitorprognostic factorsMedical physics. Medical radiology. Nuclear medicineR895-920ENRadiology and Oncology, Vol 55, Iss 4, Pp 491-498 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pd-l1 inhibitor urothelial cancer bladder atezolizumab overall survival immune checkpoint inhibitor prognostic factors Medical physics. Medical radiology. Nuclear medicine R895-920
spellingShingle	pd-l1 inhibitor urothelial cancer bladder atezolizumab overall survival immune checkpoint inhibitor prognostic factors Medical physics. Medical radiology. Nuclear medicine R895-920 Mencinger Marina Mangaroski Dusan Bokal Urska Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
description	Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.
format	article
author	Mencinger Marina Mangaroski Dusan Bokal Urska
author_facet	Mencinger Marina Mangaroski Dusan Bokal Urska
author_sort	Mencinger Marina
title	Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
title_short	Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
title_full	Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
title_fullStr	Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
title_full_unstemmed	Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
title_sort	disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
publisher	Sciendo
publishDate	2021
url	https://doaj.org/article/e129ffa1f0f8468498cf304d0108d71e
work_keys_str_mv	AT mencingermarina diseasecontrolwithpriorplatinumbasedchemotherapyisprognosticforsurvivalinpatientswithmetastaticurothelialcancertreatedwithatezolizumabinrealworldpractice AT mangaroskidusan diseasecontrolwithpriorplatinumbasedchemotherapyisprognosticforsurvivalinpatientswithmetastaticurothelialcancertreatedwithatezolizumabinrealworldpractice AT bokalurska diseasecontrolwithpriorplatinumbasedchemotherapyisprognosticforsurvivalinpatientswithmetastaticurothelialcancertreatedwithatezolizumabinrealworldpractice
_version_	1718371329847066624

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Ejemplares similares